sTLR2 RAPID Test with applications in sepsis and inflammation

J R Biomedical Ltd

St Asaph, United Kingdom

With applications in sepsis and inflammation, we have developed in cooperation with Cardiff University, a 10 minute rapid test and proprietary panel of monoclonal and polyclonal antibodies, that detect the innate immune system biomarker soluble Toll-like receptor 2 (sTLR2). UKCA certified ISO13485:2016 certified Results in 10 minutes 20µL blood sample J R Biomedical Ltd. is a British ISO13485 certified in-vitro diagnostics company who have developed a panel of proprietary antibodies, and a rapid diagnostic IVD to detect plasma soluble Toll-like receptor 2 (sTLR2), a biomarker known to be elevated in sepsis. UK Patent Application GB2502531.3. An independent study of sTLR2 versus CRP in critically ill patients showed that sTLR2 had better specificity and sensitivity for sepsis than C-reactive protein, the most commonly used marker in the ICU. Further, low sTLR2 levels had good ability to rule out sepsis within the first 12 h of ICU stay, when clinical parameters and traditional markers of infection are often equivocal.